机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.[2]Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan, China.四川大学华西医院[3]National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China.[4]Department of Hematology, The Second People’s Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.深圳市第二人民医院深圳市康宁医院深圳医学信息中心[5]Department of Hematology, Sichuan Academy of Medical Sciences Sichuan Provincial People’s Hospital, Sichuan, China.四川省人民医院[6]Peking University People’s Hospital, Qingdao, China.[7]Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China.[8]Department of Hematology, Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.华中科技大学同济医学院附属同济医院[9]Department of Hematology, Shenzhen Hospital of Southern MedicalUniversity, Shenzhen, China.深圳市康宁医院深圳医学信息中心[10]Department of Hematology, Xi’an international medical center hospital, Xi’an, China.[11]Department of Hematology, Weifang People's Hospital, Weifang, China.[12]Department of Hematology, The First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Zhejiang, China.浙江大学医学院附属第一医院[13]Department of Hematology, Binzhou Medical University Hospital, Binzhou, China.[14]Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing, China.[15]Department of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.云南省第一人民医院[16]Department of Hematology, The People's Hospital of Xing'an League, Ulanhot, Inner Mongolia Autonomous Region, China.[17]Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.江苏省人民医院[18]Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China.[19]Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China.[20]Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.广东省人民医院[21]Department of Immunology and Inflammation, Centre for Hematology, Imperial College London, London, United Kingdom.[22]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China[23]Department of Hematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Henan, China.河南省肿瘤医院
Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia (CML) is important to increase safety without compromising efficacy. We designed a multi-center retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other day (QOD; N = 216) and a reduced dose of 30 mg QOD (N = 66) in subjects failing other tyrosine kinase-inhibitors (TKIs). The cohorts were similar in baseline co-variates and adjusted for by propensity score matching (PSM). There were no significant differences in cytogenetic and molecular responses, as well as outcomes between the 2 dose cohorts. However, the proportion of subjects receiving the original olverembatinib dose at the last follow-up was significantly higher in the 30 mg cohort (64% [95%Confidence Interval [CI], 53, 75%] versus 44% [37,51%]; p = 0.004). Also, the proportion of subjects receiving a reduced dose or permanently discontinuing because of adverse event was significantly lower in the 30 mg cohort (21% [9, 33%] versus 41% [34, 48%]; p = 0.003). In summary, olverembatinib, 30 mg QOD starting dose is as effective as a 40 mg starting dose but better tolerated in persons with chronic phase CML failing other TKIs.
基金：
by the National Nature Science Foundation of
China (No. 81970140 and No. 82370161).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|1 区医学
小类|2 区血液学
最新[2025]版：
大类|1 区医学
小类|2 区血液学
第一作者：
第一作者机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
共同第一作者：
通讯作者：
通讯机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.[6]Peking University People’s Hospital, Qingdao, China.
医学